Contact Us

About Us

Expression Pathology is a private biotech company advancing personalized medicine with assays that measure tumor signaling networks – at the functional protein level — in routine formalin-fixed paraffin-embedded (FFPE) patient tissue to individualize and improve cancer treatment decisions. The company develops proprietary tests to predict disease progression and drug response.

Expression Pathology also offers its Liquid Tissue®-SRM assays in collaborations with cancer drug companies in preclinical development, clinical trials and for improved companion diagnostics. A rapidly expanding collection of assays includes many of the key protein pathways for which targeted therapies are being developed, including EGFR, IGF-1R, HER3, and cSRC. We are developing a CLIA-certified facility to offer proprietary Liquid Tissue®-SRM diagnostic tests in clinical trials of drugs in development. The test may help improve patient selection for new and existing targeted drugs. The company’s long term plans include configuring its patented technology platform into a reagent instrument system that promises a new quantitative, multiplexed paradigm for molecular pathology labs worldwide.

Expression Pathology's Liquid Tissue®-SRM assays make possible multiplexed protein quantification by mass spectrometry of laser micro-dissected FFPE tissue. Formalin fixation is the standard method by which patient tissue biopsies and surgical samples are preserved worldwide. Expression Pathology is exploiting its ability to accurately measure cancer pathway proteins in standard patient tissue and core needle biopsies, to develop more informative assays that can be widely adopted in medical practice.

The key components of the company’s technology are DIRECTOR® laser microdissection that speeds up and automates precise collection of target cells for analysis from standard tissue sections and Liquid Tissue® sample preparation that makes possible complete solubilization of the protein content of this tissue. The Liquid Tissue® process works with very small amounts of tissue. The company is combining these technologies with state-of-the-art expertise in mass spectrometry to develop proprietary assays to pioneer clinical applications of protein analysis in tissue.

Join Us

We are always interested in collaborations. We collaborate with major cancer research facilities to access patient tissue from clinical trials to develop Liquid Tissue® SRM assays. To date, we’ve established collaborations with several top international clinical research centers, including the University of Texas MD Anderson Cancer Center, University Health Network/Princess Margaret and Hospital for Sick Children, Toronto, the U.S. National Cancer Institute and Children’s Oncology Group, and Cardiff University and the UK Medical Research Council.

Studies performed at Expression Pathology adhere to the Good Laboratory Practice regulations set forth by the FDA (21 CFR Part 58)